FMC’S share price has yet to recover from the announcement of the early cessation of a clinical trial of Novo’s weight-loss active pharmaceutical ingredient semaglutide (GLP-1 antagonist; Ozempic, Rybelsus) a month ago. Investors seem to see this a general thread for the business model of dialysis service and product providers, despite not much being really known and there remaining many unanswered questions.
The consensus was moderately beaten for the Q3 (revenues: +0.4%; adjusted EBIT: +2.0% ....
